Neurizon Therapeutics Limited (ASX:NUZ)

Australia flag Australia · Delayed Price · Currency is AUD
0.0960
-0.0020 (-2.04%)
Feb 19, 2026, 4:10 PM AEST
Market Cap67.49M +9.7%
Revenue (ttm)1.54M +82.7%
Net Income-16.59M
EPS-0.03
Shares Out688.63M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume113,062
Average Volume582,989
Open0.1000
Previous Close0.0980
Day's Range0.0960 - 0.1000
52-Week Range0.0790 - 0.1850
Beta1.29
RSI54.15
Earnings DateFeb 26, 2026

About Neurizon Therapeutics

Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases. The company develops drug discovery intellectual property for the treatment of neurological diseases. Its lead candidate is NUZ-001, a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases. The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024. Neur... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 4
Stock Exchange Australian Securities Exchange
Ticker Symbol NUZ
Full Company Profile

Financial Performance

In fiscal year 2025, Neurizon Therapeutics's revenue was 1.54 million, an increase of 82.70% compared to the previous year's 841,713. Losses were -16.59 million, 116.3% more than in 2024.

Financial Statements